A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Multiple Sclerosis (MS)

In brief

The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).

Key facts

Study ID

NCT03737851

Run by

AbbVie

People needed

208

Starts

2018-12-11

Expected to finish

2021-09-09

Last updated by the study team

2023-12-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has diagnosis of relapsing remitting multiple sclerosis (RRMS) or secondary-progressive multiple sclerosis (SPMS) with relapses within the past 24 months.
• Participant has cranial magnetic resonance imaging (MRI) demonstrating lesion(s) consistent with multiple sclerosis (MS).
• Participant has evidence of physical disability according to Expanded Disability Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test.

You may not qualify if…

• Participants must not have experienced or be recovering from a clinical MS relapse within 6 months of Screening.

Where it is running

• University of Alabama at Birmingham - Main /ID# 204618 — Birmingham, Alabama, United States
• St. Josephs Hospital and Med Center /ID# 204197 — Phoenix, Arizona, United States
• Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249 — Berkeley, California, United States
• The Research Center of Southern California /ID# 204269 — Carlsbad, California, United States
• Vladimir Royter MD /ID# 204392 — Hanford, California, United States
• UC Irvine Health /ID# 205728 — Irvine, California, United States
• Stanford MS Center /ID# 204283 — Palo Alto, California, United States
• UC Davis Health-Neurological Surgery /ID# 204188 — Sacramento, California, United States
• UCSF School of Medicine - Neurology /ID# 204251 — San Francisco, California, United States
• University of Colorado School of Medicine /ID# 204250 — Aurora, Colorado, United States
• Advanced Neurosciences Research, LLC /ID# 204289 — Fort Collins, Colorado, United States
• The University of Chicago Medical Center /ID# 205319 — Chicago, Illinois, United States
• Indiana Univ School Medicine /ID# 204891 — Indianapolis, Indiana, United States
• Rowe Neurology Institute /ID# 204391 — Lenexa, Kansas, United States
• The NeuroMedical Center /ID# 204253 — Baton Rouge, Louisiana, United States
• Ochsner Medical Center /ID# 204189 — New Orleans, Louisiana, United States
• Duplicate_Parexel International /ID# 204273 — Baltimore, Maryland, United States
• International Neurorehabilitation Institute /ID# 213332 — Lutherville, Maryland, United States
• Pediatric Endocrine Associates /ID# 204279 — Boston, Massachusetts, United States
• Michigan Institute for Neurological Disorders (MIND) /ID# 204194 — Farmington Hills, Michigan, United States
• Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206328 — Owosso, Michigan, United States
• Ridgeview Specialty Clinic Chaska - Neurology /ID# 204383 — Chaska, Minnesota, United States
• Washington University-School of Medicine /ID# 204388 — St Louis, Missouri, United States
• The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205433 — St Louis, Missouri, United States
• Cleveland Clinic Lou Ruvo Cent /ID# 204745 — Las Vegas, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.